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Abstract
Background and aims—Osteoarthritic patients treated with high doses of chondroitin sulfate 
(CS) have a lower incidence of coronary heart disease – but the mechanistic aspects of these 
beneficial effects of CS remain undefined. We examined how CS treatment affects the formation 
of atheroma via interaction with endothelial cells and monocytes.
Methods—We characterized arterial atheromatous plaques by multiphoton microscopy and 
serum pro-inflammatory cytokines by immunoenzymatic techniques in obese mice receiving CS 
(1g/Kg/day, i.p.) or vehicle for 6 days. Effects of CS on signaling pathways, cytokine secretion 
and macrophage migration were evaluated in cultures of human coronary endothelial cells and in a 
monocyte cell line stimulated with TNF-α by Western blot, immunoenzymatic techniques and 
transwell migration assays.
Results—Treatment of obese mice with CS reduced the extension of foam cell coverage in 
atheromatous plaques of arterial bifurcations by 62.5%, the serum concentration of IL1β by 70%, 
TNF-α by 82% and selected chemokines by 25–35%. Cultures of coronary endothelial cells and 
monocytes stimulated with TNF-α secreted less pro-inflammatory cytokines in the presence of CS 
(P<0.01). CS reduced the activation of the TNF-α signaling pathway in endothelial cells (pErk 
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36% of reduction, and NFκB 33% of reduction), and the migration of activated monocytes to 
inflamed endothelial cells in transwells (81±6 vs.13±2, P<0.001).
Conclusions—CS interferes with the pro-inflammatory activation of monocytes and endothelial 
cells driven by TNF-α thus reducing the propagation of inflammation and preventing the 
formation of atherosclerotic plaques.
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Introduction
Obesity and atherosclerosis are chronic inflammatory processes very closely integrated, 
characterized by activation of immune system and endothelium where TNF-α plays a 
pivotal role.1–4 Circulating monocytes adhere to inflamed endothelium, infiltrate 
atherosclerotic lesions, differentiate into macrophages5–6, and deliver pro-inflammatory 
mediators such as TNF-α which participate decisively in the development and exacerbation 
of atherosclerosis.7–8
Glycosaminoglycans are large linear polysaccharides constructed of repeating disaccharide 
units. Among them, heparan sulfate has been suggested as critical to regulation of vascular 
repair after injury and promoting atherogenesis.9–10 The glycosaminoglycan chondroitin 
sulfate (CS) has traditionally being associated to the prevention of cardiac events, but its role 
in atherosclerosis has not been completely elucidated as yet. In the early 70s, 60 patients 
with coronary heart disease treated with commercial CS showed a seven-fold lower 
incidence of coronary events compared to the control group11. After 6 years of follow-up, 
only 10% of those CS-treated patients presented an acute cardiac event, of which four died, 
compared with 70% of which 14 died in the control group.12 Few years later, a different 
clinical trial showed similar beneficial effects of CS therapy in mortality on atherosclerotic 
subjects.13 However, since then, the therapeutic use of CS has been focused mainly to the 
treatment of osteoarthritis as CS is present in the extracellular matrix (ECM) especially in 
the cartilage, skin, blood vessels, ligaments and tendons.14 Recently, new evidences raised 
in patients with osteoarthritis and CS therapy. Interestingly, osteoarthritic patients treated 
with CS showed a reduction of seven-fold in the incidence of coronary events.15 Animal 
studies have demonstrated the anti-inflammatory potential of CS inhibiting hind paw 
oedema, synovitis and destruction of the articular cartilage in a dose-dependent manner.16 In 
advanced atherosclerosis, there is now a notion that there is a decrease in CS 4S (mainly 
composed of glucuronic acid and galactosamine residues sulfated in position 4; the 
disaccharides are Δdi-4S) and/or CS 6S (mainly composed of Δdi-6S), with a concomitant 
increase in arterial walls of dermatan sulfate (CS with the glucuronic acid moiety is replaced 
by its C-5 epimer, the iduronic acid).14 Administration of CS 6S has been described to 
interfere with the proinflammatory response of activated murine macrophages17, but no 
studies have described the potential immunomodulatory effects of CS in atherogenesis. We 
therefore aimed to investigate whether CS could modulate inflammation in activated 
monocytes and endothelial cells to prevent atherogenesis in obese mice.
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Materials and Methods
Animal studies
Male Diet Induced Obesity (DIO) mice were purchased from the Jackson Laboratory (Bar 
Harbor, ME). All animals were maintained in a temperature-controlled room (22°C) on a 12-
h light-dark cycle under institutional and NIH guidelines. After arrival, mice were 
continuously fed ad libitum with high fat diet (60% of Kcal from fat) until euthanasia. CS (1 
g/kg/day from bovine origin with a disaccharide sulfation profile of 63% of 4-sulfated, 31% 
of 6-sulfated and 6% of O-sulfated; Bioibérica, Barcelona, Spain) or saline solution 
(Vehicle, VH) was intraperitoneally injected for 6 days. Afterwards animals were sacrificed 
and blood samples obtained and processed by standard procedure to obtain serum for 
Multiplex ELISA arrays (Quansys Bioscience Inc., Logan, UT) of the cytokines IL-1β, IL-6, 
IL-10, TNF-α, MIP-1α, KC, MCP-1, RANTES, TARC. Animal experiments were approved 
by the Animal Ethics Committee at Massachusetts Institute of Technology, MA, USA.
Whole-mount multiphoton imaging of macrophage presence and angiography in carotid 
bifurcations
Obese mice (14 weeks old) treated or non-treated with CS were anesthetized with isoflurane, 
injected with 100 µL of 20 mg/mL 70-kDa Texas red-dextran in PBS into the tail vein and, 
after 6 hours, euthanized by overexposure to CO2, and intracardially perfused with 
fluorescein isothiocyanate-labeled dextran (FITC-dextran, MW 2x106 Da., Sigma, St. Louis, 
MO). Carotid bifurcations and macrophage fluorescence were visualized using a 
multiphoton intravital microscope (Leica Microsystems, Heerbrugg, Switzerland). The 
description of this method is expanded in the Online Data Supplement.
Cell culture and live-dead assay
Human coronary artery endothelial cells (HCAEC) were grown on Endothelial Growth 
Medium-2 (EGM-2, Lonza, Walkersville, MD, USA) and the human monocyte cell line 
THP-1 on DMEM supplemented with 10% fetal bovine serum. HCAEC or THP-1 were 
seeded on 6-well plates at a density of 2×105 cells/well. Then, cells were pre-treated with 
either CS (200 µg/mL) or prednisolone (10 µmol/L) for 24 hours and continuously treated 
when stimulated with TNF-α (3 ng/ml) for 16 hours. Conditioned media was obtained after 
additional 24 hours with TNF-α free media and used for multiplex ELISA arrays of 
cytokines and chemokines (Quansys Biosciences, Logan, UT, USA). Cytotoxicity was 
tested using a Live/Dead assay (Life Technologies, Grand Island, NY, USA). The 
description of this method is expanded in the Online Data Supplement.
In vitro migration assay
Migration of the human monocyte cell line (THP-1 cells) to HCAEC, was quantified in 24-
well plate Transwell inserts with a 5 µm porous membrane (Corning) with or without PMA 
(100 ng/mL) in the presence or absence of CS or Prednisolone (200 µg/mL) or in the 
presence or the absence of TNF-α (3 ng/mL) for 16h. Cell migration was allowed for 16 
hours. Nuclei of migratory cells on the lower side of the membrane were stained with 4’,6-
diamidino-2-phenylindole (DAPI, Vectashield, Vector laboratories, Burlingame, CA) and 
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quantified in 6 different fields per sextuplicate using the ImageJ software. The description of 
this method is expanded in the Online Data Supplement.
Western blotting
Cell samples were lysed in RIPA buffer solution (Sigma, St Louis, MO) containing a 
cocktail of protease inhibitors (Sigma P8340). Whole lysates were used afterwards for the 
analysis of protein abundance of PhosphoErk/Erk, phosphoJnk/Jnk and NFkB. The 
description of this method is expanded in the Online Data Supplement.
Gene expression analysis by Real-Time PCR
Briefly, total RNA from HCAEC and THP-1 was extracted using RNeasy kit (Gibco-
Invitrogen, Paisley, UK). A 1 µg of total RNA was reverse transcribed using a 
complementary DNA synthesis kit (High-Capacity cDNA Reverse Transcription Kit, 
Applied Biosystems, Foster City, California, USA). Taqman primers and probes for gene 
expression assays were selected from Applied Biosystems for human IL-6, IL-8, TNF-α and 
IL-1β. The description of this method is expanded in the Online Data Supplement.
Statistical analysis
Data are expressed as mean ± standard error. Statistical analysis of the results was 
performed by one-way analysis of variance (ANOVA), the Newman-Keuls test, and the 
unpaired Student’s t test when appropriate. Differences were considered to be significant at 
a p value of 0.05 or less. Data sampled from Gaussian populations were used for the 
calculation of Pearson Correlation Coefficient. A Pearson correlation coefficient (r) value of 
>0.75 was considered to exhibit strong positive correlation between two variables.
Results
Administration of CS ameliorates the inflammatory profile and the extension of 
atherosclerotic plaques in obese mice
DIO obese mice treated with CS showed lower serum levels of the mediators of the 
inflammatory response IL-1β and TNF-α than animals receiving vehicle (Figure 1A). These 
cytokines are mainly released by activated monocytes and macrophages.8 Moreover we also 
found a significant reduction of the serum concentration of the chemotactic factors KC, 
RANTES and TARC in animals treated with CS as compared with control animals (Figure 
1B). Those factors are mainly released by endothelium in response to inflammatory stimuli.8 
The anti-inflammatory effects of CS in obese mice were also associated with a drastic 
reduction in the extension of the macrophage presence in the layers of arterial bifurcations 
(Figure 1C).
CS treatment disrupts the TNF-α-induced release of leucocyte activators and chemokines 
in HCAEC via Erk and NFκB signaling
Incubation of HCAEC with TNF-α produced an increase in the release of phagocyte 
activators IL-6 and IL-8 (Figure 2A), and also a proportional raise of both mRNA levels 
(Supplementary Figure 1). These increased values were attenuated when HCAEC were 
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treated either with prednisolone or CS (Figure 2A and Supplementary Figure 1). Likewise, 
incubation of inflamed HCAEC with CS partially prevented the release of the chemokines 
GRO- α, MCP-1, RANTES and IP-10 showing similar outcomes to the anti-inflammatory 
drug prednisolone (Figure 2B). Treatment of inflamed HCAEC with CS also prevented the 
increase of the biomarker of inflammation C-reactive protein (Figure 2C). The anti-
inflammatory effects of CS in inflamed HCAEC were related to the disruption of both the 
phosphorylation of the protein extracellular signal-regulated kinase (Erk) and the 
downstream activation of NFκB (Figure 2D). No toxic effects of any of the treatments were 
observed in HCAEC (Supplementary Figure 2).
CS treatment interferes with the release of inflammatory cytokines in activated monocytes 
and macrophages
We activated the human cell line of monocytes THP-1 with TNF-α and analyzed the profile 
of the cytokines released by these cells in contact with CS, and identified higher release of 
TNF-α, IL-1β, IL-6 and IL-12 when compared with vehicle - an increase that was partially 
or totally abolished with the use of CS or Prednisolone (Figure 3A). To a lesser extent, IL-4, 
IL-8, IL-10, IL-15 and IL-23 levels also rose significantly with the presence of TNF-α and 
dropped to normal when these cells were incubated with CS or prednisolone (Figure 3A). 
Accordingly, TNF-α up-regulated the mRNA expression of TNF-α, IL-1β, IL-6 and IL-8, 
and the treatment with CS or Prednisolone obliterated the expression of these cytokines 
(Supplementary Figure 3A). To investigate whether CS could also prevent the pro-
inflammatory profile of macrophages, we induced the differentiation of monocytes to 
macrophages with PMA for 2 days and analyzed their profile of cytokine release. Similar to 
monocytes activated by TNF-α, macrophages displayed a higher release of TNF-α, IL-1β, 
IL-6, IL-12 and also IL-10 than monocytes treated with vehicle in a manner partially or 
totally obliterated with the use of CS or Prednisolone (Figure 3B). Interestingly, the levels of 
IL-8 released by macrophages were more than 1000 fold-higher than in monocytes receiving 
vehicle (Figure 3B) or than monocytes treated with TNF-α. The levels of all of these 
cytokines were reduced with the treatment of CS or Prednisolone. To a lesser extent, IL-4, 
IL-15 and IL-23 levels also rose significantly in macrophages and dropped when these cells 
were incubated with CS or Prednisolone (Figure 3B). Accordingly, macrophages displayed 
higher mRNA expression of TNF-α, IL-1β, IL-6 and IL-8 than monocytes, and the treatment 
with CS or Prednisolone significantly reduced the expression of these cytokines 
(Supplementary Figure 3B).
CS plays a dual role reducing the migration of macrophages to inflamed HAECs
We incubated Transwell inserts containing macrophages differentiated by PMA with HAEC 
in the presence or absence of TNF and CS or Prednisolone. Macrophages migrated through 
the other side of the membrane at a higher rate when HAEC were pre-stimulated with TNF-
α and that effect was drastically prevented when HAEC were also treated with CS or 
Prednisolone (Figure 4A). These migration outcomes are strongly positively correlated 
(r>0.75, Pearson) with the profile of cytokines and chemokines released by inflamed HAEC 
in the presence of CS (Supplementary Table 1). Likewise THP-1 human monocytes in 
Transwell inserts non treated or treated with PMA in the presence or absence of CS or 
Prednisolone were incubated with HAEC inflamed with TNF-α. CS, but also prednisolone, 
Melgar-Lesmes et al. Page 5
Atherosclerosis. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
considerably reduced the number of monocytes differentiating and transmigrating to the side 
of the membrane in contact with inflamed HCAECs (Figure 4B). These migration outcomes 
strongly positively correlated with the profile of cytokines secreted by activated monocytes 
in the presence of CS (Supplementary Table 2).
Discussion
Cardiovascular disease is the leading cause of death in many industrialized countries, and 
atherosclerosis is the most important underlying pathology.8 Atherosclerosis is characterized 
by accumulation of lipids and an inflammatory response in the arterial intima, resulting in 
the formation of plaque that is susceptible to rupture and cause an acute coronary event.18 
TNF-α, a pleiotropic cytokine released by adipose tissue in obesity, exerts major modulatory 
effects in the pathogenesis of atherosclerosis.2–3,19 The non-genetically modified DIO 
animal model (high fat diet) resembles the chronic inflammation and metabolic disorders 
that lead to acute and chronic vascular injury in atherosclerosis.20–21 Our in vivo outcomes 
showing reduction of both number of macrophages in arteries and serum inflammatory 
cytokines in CS-treated obese mice pointed to a possible role of CS interfering with the 
inflammatory response of endothelium and monocytes in obesity. For that reason we 
analyzed the effects of the treatment of CS in inflamed HCAEC and monocytes THP-1.
We describe herein for the first time, to our knowledge, the main cellular mechanism by 
which CS controls the atherogenic milieu. CS interacts with the main local cells involved in 
the atherosclerotic process, that is, endothelial cells and monocytes. CS interaction with 
TNF-α-inflamed coronary endothelial cells or monocytes reduces the secretion of IL-6, 
IL-8, C-Reactive protein and chemokines by endothelial cells and the secretion of IL1-β and 
TNF-α by monocytes and macrophages. This explains part of the in vivo effects of CS on 
the cytokine profile in obese mice. Interestingly, CS also interferes with the TNF-α-induced 
secretion of IL-6 and IL-8 in monocytes and macrophages. These two locally secreted 
cytokines are directly related to some adipokines relevant in modulating atherosclerosis, and 
they are also a risk factor in future coronary artery disease in healthy population.22–26 
Furthermore, they can act synergistically in association with C-reactive protein27 and other 
cytokines (e.g. IL-4, IL-10, IL-12, IL-15, IL-23) and markedly amplify their activity either 
inducing their expression or regulating the expression of cytokine receptors.8 This together 
with the fact that we showed how CS treatment prevents the activation of monocytes to 
differentiate and migrate to the inflamed endothelium supports the hypothesis that CS 
treatment reduces atherogenesis via a dual way of action: CS interacts with endothelial cell 
matrix to prevent TNF-α-mediated pro-inflammatory effects; and CS interacts with cell 
matrix of monocytes and macrophages preventing their activation and migration. The data 
presented here give insight into how CS reduces cardiovascular events by interfering with 
the promotion of atherogenesis. CS appears as a candidate to be used in the prevention of 
atherosclerotic cardiovascular events in obese population.
Limitations and Strengths
This report provides a new insight into the role of CS in the activation of pro-inflammatory 
pathways that are shared between obesity and atherogenesis. However, this study provides a 
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proof of concept of beneficial effects of CS only at the level of prevention of mild 
atherosclerotic plaque formation. In clinical trials CS demonstrated to protect from 
cardiovascular events. Therefore animal experiments using models of advanced 
atherosclerosis and cardiovascular disease are needed to assess the effects of CS in unstable 
plaques and in mortality due to cardiovascular events.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
- CS therapy reduces macrophage presence in arterial plaques in obese mice.
- CS therapy reduces pro-inflammatory cytokines in obese mice.
- CS interacts with monocytes and endothelial cells reducing TNF-α effects.
- CS reduces migration of monocytes to inflamed endothelial cells.
- CS offers a totally safe strategy to reduce the risk of atherosclerosis in 
obesity.
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Figure 1. Effects of CS treatment on the profile of pro-inflammatory cytokines in obese mice
Ten serum samples from diet-induced obesity (DIO) mice receiving vehicle (VH) and ten 
serum samples from mice receiving chondroitin sulfate A (CS) (1000 mg/kg/day) for 6 days 
were used to test a panel of inflammatory cytokines A and chemokines B. *p<0.01 and 
***p<0.0001 vs. VH samples. C, Effects of CS treatment in the number of macrophages in 
atherosclerotic plaques in “in situ” carotid arterial bifurcations of obese mice. 
Representative images of multiphoton microscopy from animals receiving vehicle (VH, 
n=8) or chondroitin sulfate A (CS, n=8). Quantification of macrophage area coverage is 
shown to the right. Mice were perfused first with dextran-Texas red in order to induce 
phagocytosis of macrophages and after with dextran-FITC to stain arteries. Macrophages are 
shown in yellow. Original magnification, ×25; ***, p<0.0001 vs. VH samples.
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Figure 2. Effects of CS treatment on the profile of release of pro-inflammatory cytokines in 
inflamed human coronary artery endothelial cells (HCAEC)
Cell supernatants from non-inflamed HCAEC (VH), inflamed with TNF-α (3 ng/mL, 16 h) 
or inflamed and treated with Prednisolone (Pred, 10 µmol/L) or CS (200 µg/mL) were used 
to test a panel of human inflammatory cytokines A, chemokines B and C-reactive protein C 
by using ELISA arrays. D, Analysis of the effects of CS in the phosphorylation and 
subsequent activation of extracellular signal-regulated kinases (Erk) and NFκB in the TNF-
α signaling pathway in HCAEC. Protein lysates were obtained from non-inflamed HCAEC 
(VH), inflamed with TNF-α (3 ng/mL, 16 h) or inflamed and treated with Prednisolone 
(Pred, 10 µmol/L) or CS (200 µg/mL) to perform western Blotting and densitometric 
analysis of protein bands. Non-phosphorylated Erk or β-actin was used as a loading control. 
*, p<0.05 and **, p<0.01 vs. VH samples; #, p<0.05 and ##, p<0.01 vs. TNF-α samples; %, 
p<0.05 and %%, p<0.01 vs. TNF-α samples. Experiments were carried out per sextuplicate 
in two independent experiments.
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Figure 3. Effects of CS treatment on the profile of secreted pro-inflammatory cytokines in the 
human monocytic cell line THP-1 activated with TNF-α
A, Cell supernatants from non-activated THP-1 (VH), inflamed with TNF-α (3 ng/mL, 16 h) 
or inflamed and treated with CS (200 µg/mL) or Prednisolone (Pred, 10 µmol/L) were used 
to test a panel of human inflammatory mediators (TNF-α, IL-1β, IL-4, IL6, IL-8, IL-10, 
IL-12, IL-15 and IL-23) by ELISA arrays. B, Cell supernatants from non-differentiated 
THP-1 (VH), differentiated into macrophages with phorbol myristate acetate (PMA, 100 
ng/mL for 2 days) or differentiated with PMA and treated with CS (200 µg/mL) or 
Prednisolone (Pred, 10 µmol/L) were used to test a panel of human inflammatory mediators 
as above by ELISA arrays; *, p<0.05 and **, p<0.01 vs. VH samples; #, p<0.05 and ##, 
p<0.01 vs. TNF-α samples; %, p<0.05 and %%, p<0.01 vs. TNF-α samples. Experiments 
were carried out per sextuplicate in two independent experiments.
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Figure 4. CS effects on migration of activated monocytes and macrophages
A, Migration assay was performed in THP-1 monocytes incubated with PBS (VH), inflamed 
with TNF-α (3 ng/mL, 16 h) or inflamed and treated with CS (200 µg/mL) or Prednisolone 
(Pred, 10 µmol/L). Representative images show cell nuclei of migrated THP-1 macrophages 
stained with 4',6-diamidino-2-phenylindole (DAPI). Nuclei were detected by 
epifluorescence microscopy (original magnification, ×100). Quantification was carried out 
by counting fluorescent cells and is shown on the right. B, Representative images of the 
migration assay from non-differentiated THP-1 (VH), differentiated into macrophages with 
phorbol myristate acetate (PMA, 100 ng/mL for 2 days) or differentiated with PMA and 
treated with CS (200 µg/mL) or Prednisolone (Pred, 10 µmol/L). Quantification was carried 
out as above and shown on the right. ***, p<0.0001 vs. VH samples; ###, p<0.0001 vs. 
TNF-α samples; %%%, p<0.0001 vs. TNF-α samples. Experiments were carried out per 
sextuplicate in two independent experiments.
Melgar-Lesmes et al. Page 13
Atherosclerosis. Author manuscript; available in PMC 2017 February 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
